<DOC>
	<DOCNO>NCT00227305</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety quetiapine fumarate ( SEROQUEL ) treatment adolescent patient schizophrenia bipolar I disorder .</brief_summary>
	<brief_title>Quetiapine Fumarate ( SEROQUEL ) Treatment Adolescent Patients With Schizophrenia Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient able provide write assent parent legal guardian patient are/is able provide write informed consent begin study related procedure Patient previously enrol either doubleblind Study D1441C00149 D1441C00112 Patient document clinical diagnosis schizophrenia bipolar I disorder Patient 's parent legal guardian able accompany patient schedule study visit Patients ( female ) must pregnant lactating Patients know intolerance lack response previous treatment quetiapine Patients previously participate study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar I Disorder</keyword>
</DOC>